Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × INDUSTRY × Contraceptives, Oral × Clear all

Phase

Phase 1 2 Phase 4 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1

Interventions

Zoledronic Acid 23 Bevacizumab 13 nilotinib 12 Docetaxel 12 Paclitaxel 11 Everolimus 11 Letrozole 10 Imatinib Mesylate 10 Capecitabine 10 Erlotinib Hydrochloride 9 Drug Therapy 9 Carboplatin 9 pegfilgrastim 8 enzalutamide 8 Trastuzumab 7 Oxycodone 7 Nivolumab 7 Imiquimod 7 Gemcitabine 7 Epoetin Alfa 7 icotinib 6 Rituximab 6 Prednisone 6 Pemetrexed 6 Oxaliplatin 6 Leuprolide 6 Fulvestrant 6 Diclofenac 6 Dexamethasone 6 Cisplatin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05340634 2022-04-28

Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.

Margan Biotech

Phase 4 Completed

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡